BARD1 CEO, Dr Leearne Hinch, said: “This is an important milestone, enabling us to confidently advance
the development of a commercial BARD1 autoantibody test for ovarian cancer on the Luminex platform.
Additionally, the Luminex platform can be applied for development of other tests using our BARD1
autoantibody approach for breast and lung cancers.”
Ann: Successful BARD1 Kit Evaluation, page-55
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.5¢ |
Change
-0.020(3.42%) |
Mkt cap ! $62.30M | |||
| Open | High | Low | Value | Volume |
| 57.5¢ | 57.5¢ | 56.5¢ | $21.90K | 38.41K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4193 | 56.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 57.5¢ | 2000 | 1 |
View Market Depth
| Last trade - 15.33pm 11/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |